✦ LIBER ✦

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

✍ Scribed by Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann

Book ID: 117289963
Publisher: The Lancet
Year: 2005
Tongue: English
Weight: 105 KB
Volume: 366
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(05)67059-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P81 Benefits of switching postmenopausal

P81 Benefits of switching postmenopausal women withhormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial

✍ M. Kaufmann; R. Jakesz; M. Gnant; W. Jonat; M. Mittlboeck; R. Greil; C. Tausche; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 146 KB

0138 ABCSG-16/SALSA: Prospective, open,

0138 ABCSG-16/SALSA: Prospective, open, randomised, multicentre phase III study to assess extended adjuvant treatment with 2 or 5 years' anastrozole in postmenopausal women with endocrine-responsive early breast cancer after 5 years of initial adjuvant endocrine therapy

✍ M. Gnant; B. Mlineritsch; P. Dubsky; C. Menzel; W. Schippinger; D. Manfreda; S. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

Switching to exemestane after 2–3 years

Switching to exemestane after 2–3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen: Abstracted from: Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92.

✍ Christina Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 248 KB